Full-Time

Director – Project Management

IQVIA Biotech

Posted on 7/3/2025

IQVIA

IQVIA

10,001+ employees

Analytics and research for life sciences

No salary listed

Expert

Madrid, Spain + 1 more

More locations: Reading, UK

In Person

Category
Project Management
Business & Strategy
Required Skills
Risk Management
Google Cloud Platform
Requirements
  • 12 years of prior relevant experience, including substantial project management or relevant functional experience
  • At least 7 years experience in Ophthalmology, Respiratory, or Gastrointestinal diseases
  • Knowledge of clinical trials - In depth knowledge and skill in applying applicable clinical research regulatory requirements; i.e. Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines
  • Strong understanding of Clinical Research industry and the relevant environments in which it operates
Responsibilities
  • Participate in bid defense preparations
  • Lead bid defense presentations in partnership with Business Development
  • Support development of project strategy and operationalize the agreed upon approach
  • Develop and/or support on the preparation of integrated study management plans in collaboration with the core project team
  • Accountable for the strategic development and execution or delivery of clinical studies in line with agreed upon contracts while optimizing speed, quality and cost of delivery
  • Serve as primary project oversight and/or contact with customers and own relationship with the project’s key customer contact(s)
  • Set objectives for the core project team according to agreed upon contract, strategy and approach
  • Effectively communicate and assess performance, providing feedback and leadership
  • Collaborate with other functional groups within the company where necessary to support milestone achievement and to manage study issues and obstacles
  • Monitor progress against contract and prepare/present project information proactively to all stakeholders internally and externally
  • Supervise problem solving and resolution efforts to include management of risk, contingencies and issues
  • Take accountability for proactive contingency plans to mitigate risks
  • Coach and/or mentor junior team members around project delivery, planning, project review, risk management and problem solving
  • Achieve project quality by identifying and proactively managing quality risks and issues
  • Responding to issues raised by project team members and planning/implementing appropriate corrective and preventative action plans
  • May participate in executive committees as part of program leadership
  • Ensure the financial success of the project including optimal management and assignment of resources to achieve project goals and profitability
  • Forecast and identify opportunities to accelerate activities to bring milestones and revenue forward
  • Identify changes in scope and manage change control process
  • Identify and communicate lessons learned and best practices to promote continuous improvement
  • Adopt corporate initiatives and changes, and serve as a change advocate when necessary
  • Provide input to line managers on their project team members’ performance relative to project tasks
  • Support staff development
  • Mentor less experienced project team members on assigned projects to support their professional development

IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main product, IQVIA Connected Intelligence™, utilizes big data and technology to offer insights that help clients speed up the development and marketing of new medical treatments. This system connects various healthcare data points to provide a comprehensive view of patient needs and treatment effectiveness. Unlike many competitors, IQVIA places a strong emphasis on patient privacy, using advanced technologies to protect individual data. The company's goal is to enhance healthcare outcomes by supporting biotech, pharmaceutical, and medical device companies, as well as researchers and government agencies, in their efforts to understand diseases and improve treatment options.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • IQVIA leads in decentralized clinical trial technologies, enhancing market position.
  • The Med-R1 8B LLM launch boosts clinical data interpretation capabilities.
  • Recognition for patient engagement app highlights digital health tool importance.

What critics are saying

  • Healthcare industry's profit-driven model scrutiny may increase regulatory pressures.
  • Access disparities in CAR T-cell therapy could hinder market penetration.
  • Reliance on senior notes for financing exposes IQVIA to financial risks.

What makes IQVIA unique

  • IQVIA's Connected Intelligence™ offers unique insights across healthcare sectors.
  • The company excels in patient privacy with advanced privacy-enhancing technologies.
  • IQVIA's Med-R1 8B LLM outperforms larger models in medical reasoning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Company News

IQVIA
Jun 25th, 2025
IQVIA wins the Fierce CRO Award for Innovative Approaches to Patient-Centric Research

IQVIA wins the Fierce CRO Award for Innovative Approaches to Patient-Centric Research.

Business Wire
Jun 3rd, 2025
IQVIA Announces Pricing of Senior Notes

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in...

IQVIA
Jun 3rd, 2025
IQVIA announces offering of senior notes

<p> <strong>RESEARCH TRIANGLE PARK, N.C.</strong> &ndash; IQVIA Holdings Inc. (&ldquo;IQVIA&rdquo;) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the &ldquo;Issuer&rdquo;), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the &ldquo;Notes&rdquo;). </p> <p> The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer&rsquo;s revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. </p> <p> This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum. </p> <br /> <h5> About IQVIA </h5> <p> IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA&rsquo;s portfolio of solutions are powered by IQVIA Connected Intelligence&trade; to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI&trade;, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. </p> <p> IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA&rsquo;s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. </p> <br /> <h5> Forward Looking Statements </h5> <p> Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially. </p> <br /> <h5> IQVIAFIN </h5> <p> Kerri Joseph, IQVIA Investor Relations (<a href="mailto:[email protected]">[email protected]</a>)<br /> +1.973-541-3558 </p>

IQVIA
Jun 1st, 2025
IQVIA Health Research Space wins 2025 Medtech Breakthrough Award for 'Best Mobile App for Patient Engagement'

Research Triangle Park, N.C., - June 16, 2025 - IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program.

PR Newswire
May 19th, 2025
Vimergy Launches The "Mouth Of America" - Exposing A System That Profits When We Stay Sick

New National Campaign Confronts the Healthcare Industry's Perverse Incentives and Sparks a Movement for Preventive WellnessNEW YORK, May 19, 2025 /PRNewswire/ -- Vimergy, the premium supplement company helping people reclaim their health with pure, potent, and timeless products, today launched the "Mouth of America" – an immersive national campaign debuting a large-scale art installation in New York City. Designed to provoke and inspire, the campaign calls attention to America's real health crisis: chronic, system-driven illness fueled by a healthcare model that profits when we stay sick. This problem shows no sign of abating: In 2024, Americans collectively took 215 billion doses of prescription medication

INACTIVE